Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma.

Nywening TM, Belt BA, Cullinan DR, Panni RZ, Han BJ, Sanford DE, Jacobs RC, Ye J, Patel AA, Gillanders WE, Fields RC, DeNardo DG, Hawkins WG, Goedegebuure P, Linehan DC.

Gut. 2018 Jun;67(6):1112-1123. doi: 10.1136/gutjnl-2017-313738. Epub 2017 Dec 1.

2.

Mammaglobin-A is a target for breast cancer vaccination.

Kim SW, Goedegebuure P, Gillanders WE.

Oncoimmunology. 2016 Feb 26;5(2):e1069940. eCollection 2016 Feb.

3.

Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer.

Tiriveedhi V, Tucker N, Herndon J, Li L, Sturmoski M, Ellis M, Ma C, Naughton M, Lockhart AC, Gao F, Fleming T, Goedegebuure P, Mohanakumar T, Gillanders WE.

Clin Cancer Res. 2014 Dec 1;20(23):5964-75. doi: 10.1158/1078-0432.CCR-14-0059.

4.

Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134.

Hashim YM, Spitzer D, Vangveravong S, Hornick MC, Garg G, Hornick JR, Goedegebuure P, Mach RH, Hawkins WG.

Mol Oncol. 2014 Jul;8(5):956-67. doi: 10.1016/j.molonc.2014.03.005. Epub 2014 Mar 26.

5.

Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.

Garg G, Gibbs J, Belt B, Powell MA, Mutch DG, Goedegebuure P, Collins L, Piwnica-Worms D, Hawkins WG, Spitzer D.

BMC Cancer. 2014 Jan 21;14:35. doi: 10.1186/1471-2407-14-35.

6.

Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.

Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi GM, Gallagher WM, Wegner C, West BL, Wang-Gillam A, Goedegebuure P, Linehan DC, DeNardo DG.

Cancer Res. 2013 Feb 1;73(3):1128-41. doi: 10.1158/0008-5472.CAN-12-2731. Epub 2012 Dec 5.

7.

A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma.

Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, Simon PO, Mitchem JB, Hornick JR, Sorscher S, Picus J, Suresh R, Lockhart AC, Tan B, Hawkins WG.

Invest New Drugs. 2013 Jun;31(3):707-13. doi: 10.1007/s10637-012-9866-y. Epub 2012 Aug 4.

8.

Cross-dressed CD8α+/CD103+ dendritic cells prime CD8+ T cells following vaccination.

Li L, Kim S, Herndon JM, Goedegebuure P, Belt BA, Satpathy AT, Fleming TP, Hansen TH, Murphy KM, Gillanders WE.

Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12716-21. doi: 10.1073/pnas.1203468109. Epub 2012 Jul 16.

9.

Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands.

Hornick JR, Spitzer D, Goedegebuure P, Mach RH, Hawkins WG.

Surgery. 2012 Sep;152(3 Suppl 1):S152-6. doi: 10.1016/j.surg.2012.05.014. Epub 2012 Jul 3. Review.

10.

Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells.

Tiriveedhi V, Fleming TP, Goedegebuure PS, Naughton M, Ma C, Lockhart C, Gao F, Gillanders WE, Mohanakumar T.

Breast Cancer Res Treat. 2013 Feb;138(1):109-18. doi: 10.1007/s10549-012-2110-9. Epub 2012 Jun 8.

11.

Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer.

Hornick JR, Vangveravong S, Spitzer D, Abate C, Berardi F, Goedegebuure P, Mach RH, Hawkins WG.

J Exp Clin Cancer Res. 2012 May 2;31:41. doi: 10.1186/1756-9966-31-41.

12.

Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity.

Li Q, Rao R, Vazzana J, Goedegebuure P, Odunsi K, Gillanders W, Shrikant PA.

J Immunol. 2012 Apr 1;188(7):3080-7. doi: 10.4049/jimmunol.1103365. Epub 2012 Feb 29.

13.

Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.

Porembka MR, Mitchem JB, Belt BA, Hsieh CS, Lee HM, Herndon J, Gillanders WE, Linehan DC, Goedegebuure P.

Cancer Immunol Immunother. 2012 Sep;61(9):1373-85. doi: 10.1007/s00262-011-1178-0. Epub 2012 Jan 4.

14.

Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling.

Spitzer D, Simon PO Jr, Kashiwagi H, Xu J, Zeng C, Vangveravong S, Zhou D, Chang K, McDunn JE, Hornick JR, Goedegebuure P, Hotchkiss RS, Mach RH, Hawkins WG.

Cancer Res. 2012 Jan 1;72(1):201-9. doi: 10.1158/0008-5472.CAN-11-1354. Epub 2011 Nov 7.

15.

Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer.

Goedegebuure P, Mitchem JB, Porembka MR, Tan MC, Belt BA, Wang-Gillam A, Gillanders WE, Hawkins WG, Linehan DC.

Curr Cancer Drug Targets. 2011 Jul;11(6):734-51. Review.

16.

Potential targets for pancreatic cancer immunotherapeutics.

Dodson LF, Hawkins WG, Goedegebuure P.

Immunotherapy. 2011 Apr;3(4):517-37. doi: 10.2217/imt.11.10. Review.

17.

Cancer genome sequencing and its implications for personalized cancer vaccines.

Li L, Goedegebuure P, Mardis ER, Ellis MJ, Zhang X, Herndon JM, Fleming TP, Carreno BM, Hansen TH, Gillanders WE.

Cancers (Basel). 2011 Nov 25;3(4):4191-211. doi: 10.3390/cancers3044191.

18.

The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine.

Hornick JR, Xu J, Vangveravong S, Tu Z, Mitchem JB, Spitzer D, Goedegebuure P, Mach RH, Hawkins WG.

Mol Cancer. 2010 Nov 22;9:298. doi: 10.1186/1476-4598-9-298.

19.

Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer.

Gnerlich JL, Mitchem JB, Weir JS, Sankpal NV, Kashiwagi H, Belt BA, Porembka MR, Herndon JM, Eberlein TJ, Goedegebuure P, Linehan DC.

J Immunol. 2010 Oct 1;185(7):4063-71. doi: 10.4049/jimmunol.0902609. Epub 2010 Aug 30.

20.

A genetically encoded multifunctional TRAIL trimer facilitates cell-specific targeting and tumor cell killing.

Spitzer D, McDunn JE, Plambeck-Suess S, Goedegebuure PS, Hotchkiss RS, Hawkins WG.

Mol Cancer Ther. 2010 Jul;9(7):2142-51. doi: 10.1158/1535-7163.MCT-10-0225. Epub 2010 Jun 22.

21.

Engineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens.

Li L, Herndon JM, Truscott SM, Hansen TH, Fleming TP, Goedegebuure P, Gillanders WE.

Vaccine. 2010 Feb 23;28(8):1911-8. doi: 10.1016/j.vaccine.2009.10.096.

22.

Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer.

Johnston FM, Tan MC, Tan BR Jr, Porembka MR, Brunt EM, Linehan DC, Simon PO Jr, Plambeck-Suess S, Eberlein TJ, Hellstrom KE, Hellstrom I, Hawkins WG, Goedegebuure P.

Clin Cancer Res. 2009 Nov 1;15(21):6511-8. doi: 10.1158/1078-0432.CCR-09-0565. Epub 2009 Oct 20.

23.

Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma.

Simon PO Jr, McDunn JE, Kashiwagi H, Chang K, Goedegebuure PS, Hotchkiss RS, Hawkins WG.

Int J Cancer. 2009 Aug 15;125(4):942-51. doi: 10.1002/ijc.24424.

24.

Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma.

Kashiwagi H, McDunn JE, Simon PO Jr, Goedegebuure PS, Vangveravong S, Chang K, Hotchkiss RS, Mach RH, Hawkins WG.

J Transl Med. 2009 Mar 26;7:24. doi: 10.1186/1479-5876-7-24.

25.

Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer.

Moo-Young TA, Larson JW, Belt BA, Tan MC, Hawkins WG, Eberlein TJ, Goedegebuure PS, Linehan DC.

J Immunother. 2009 Jan;32(1):12-21. doi: 10.1097/CJI.0b013e318189f13c.

26.

Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer.

Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE, Eberlein TJ, Hsieh CS, Linehan DC.

J Immunol. 2009 Feb 1;182(3):1746-55.

27.

Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients.

Hellstrom I, Friedman E, Verch T, Yang Y, Korach J, Jaffar J, Swisher E, Zhang B, Ben-Baruch G, Tan MC, Goedegebuure P, Hellstrom KE.

Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1520-6. doi: 10.1158/1055-9965.EPI-08-0039.

28.

Generation of mammaglobin-A-specific CD4 T cells and identification of candidate CD4 epitopes for breast cancer vaccine strategies.

Viehl CT, Frey DM, Phommaly C, Chen T, Fleming TP, Gillanders WE, Eberlein TJ, Goedegebuure PS.

Breast Cancer Res Treat. 2008 May;109(2):305-14. Epub 2007 Jul 26.

PMID:
17653857
29.

Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy.

Kashiwagi H, McDunn JE, Simon PO Jr, Goedegebuure PS, Xu J, Jones L, Chang K, Johnston F, Trinkaus K, Hotchkiss RS, Mach RH, Hawkins WG.

Mol Cancer. 2007 Jul 15;6:48.

30.

TAT-Bim induces extensive apoptosis in cancer cells.

Kashiwagi H, McDunn JE, Goedegebuure PS, Gaffney MC, Chang K, Trinkaus K, Piwnica-Worms D, Hotchkiss RS, Hawkins WG.

Ann Surg Oncol. 2007 May;14(5):1763-71. Epub 2007 Jan 6.

PMID:
17206479
31.

Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.

Viehl CT, Moore TT, Liyanage UK, Frey DM, Ehlers JP, Eberlein TJ, Goedegebuure PS, Linehan DC.

Ann Surg Oncol. 2006 Sep;13(9):1252-8. Epub 2006 Sep 3.

PMID:
16952047
32.

Proteins associated with disease and clinical course in pancreas cancer: a proteomic analysis of plasma in surgical patients.

Lin Y, Goedegebuure PS, Tan MC, Gross J, Malone JP, Feng S, Larson J, Phommaly C, Trinkaus K, Townsend RR, Linehan DC.

J Proteome Res. 2006 Sep;5(9):2169-76.

PMID:
16944928
33.

Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma.

Liyanage UK, Goedegebuure PS, Moore TT, Viehl CT, Moo-Young TA, Larson JW, Frey DM, Ehlers JP, Eberlein TJ, Linehan DC.

J Immunother. 2006 Jul-Aug;29(4):416-24.

PMID:
16799337
34.

CD25+ CD4+ regulatory T-cells in cancer.

Linehan DC, Goedegebuure PS.

Immunol Res. 2005;32(1-3):155-68. Review.

PMID:
16106066
35.

Tat mammaglobin fusion protein transduced dendritic cells stimulate mammaglobin-specific CD4 and CD8 T cells.

Viehl CT, Tanaka Y, Chen T, Frey DM, Tran A, Fleming TP, Eberlein TJ, Goedegebuure PS.

Breast Cancer Res Treat. 2005 Jun;91(3):271-8.

PMID:
15952060
36.

A tat fusion protein-based tumor vaccine for breast cancer.

Viehl CT, Becker-Hapak M, Lewis JS, Tanaka Y, Liyanage UK, Linehan DC, Eberlein TJ, Goedegebuure PS.

Ann Surg Oncol. 2005 Jul;12(7):517-25. Epub 2005 May 10.

PMID:
15889213
37.

Mammaglobin-based strategies for treatment of breast cancer.

Goedegebuure PS, Watson MA, Viehl CT, Fleming TP.

Curr Cancer Drug Targets. 2004 Sep;4(6):531-42. Review.

PMID:
15462037
38.

[Significance if ICAM-1 on lysis of human pancreatic carcinoma cells by autologous, cytotoxic T-lymphocytes].

Peiper M, Goedegebuure PS, Eberlein TJ, Broelsch CE.

Langenbecks Arch Chir Suppl Kongressbd. 1998;115(Suppl I):59-62. German.

PMID:
14518213
39.

Mammaglobin-A is a tumor-associated antigen in human breast carcinoma.

Tanaka Y, Amos KD, Fleming TP, Eberlein TJ, Goedegebuure PS.

Surgery. 2003 Jan;133(1):74-80.

PMID:
12563241
40.

Induction of antigen-specific CTL by recombinant HIV trans-activating fusion protein-pulsed human monocyte-derived dendritic cells.

Tanaka Y, Dowdy SF, Linehan DC, Eberlein TJ, Goedegebuure PS.

J Immunol. 2003 Feb 1;170(3):1291-8.

41.

Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes.

Peiper M, Goedegebuure PS, Alldinger I, Knoefel WT, Izbicki JR, Eberlein TJ.

Anticancer Res. 2002 Nov-Dec;22(6A):3357-63.

PMID:
12530087
42.

Human dendritic cells induce tumor-specific apoptosis by soluble factors.

Joo HG, Fleming TP, Tanaka Y, Dunn TJ, Linehan DC, Goedegebuure PS, Eberlein TJ.

Int J Cancer. 2002 Nov 1;102(1):20-8.

43.

Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.

Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC.

J Immunol. 2002 Sep 1;169(5):2756-61.

44.

Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape.

Bernstorff WV, Glickman JN, Odze RD, Farraye FA, Joo HG, Goedegebuure PS, Eberlein TJ.

Cancer. 2002 May 15;94(10):2552-60.

45.

Modification of the HER2/NEU-derived tumor antigen GP2 improves induction of GP2-reactive cytotoxic T lymphocytes.

Tanaka Y, Amos KD, Joo HG, Eberlein TJ, Goedegebuure PS.

Int J Cancer. 2001 Nov;94(4):540-4.

46.

Loss of T-cell receptor-CD3zeta and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma.

Lockhart DC, Chan AK, Mak S, Joo HG, Daust HA, Carritte A, Douville CC, Goedegebuure PS, Eberlein TJ.

Surgery. 2001 Jun;129(6):749-56.

PMID:
11391375
47.

Expression and function of galectin-3, a beta-galactoside-binding protein in activated T lymphocytes.

Joo HG, Goedegebuure PS, Sadanaga N, Nagoshi M, von Bernstorff W, Eberlein TJ.

J Leukoc Biol. 2001 Apr;69(4):555-64.

PMID:
11310841
48.
49.

B7.1 costimulation increases T-cell proliferation and cytotoxicity via selective expansion of specific variable alpha and beta genes of the T-cell receptor.

Chan AK, Goedegebuure PS, von Bernstorff W, Carritte AL, Chung M, Stewart RA, Montgomery L, Spanjaard RA, McKenzie AB, Eberlein TJ.

Surgery. 2000 Mar;127(3):342-50.

PMID:
10715992
50.

Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu.

Peiper M, Goedegebuure PS, Izbicki JR, Eberlein TJ.

Anticancer Res. 1999 Jul-Aug;19(4A):2471-5.

PMID:
10470176

Supplemental Content

Loading ...
Support Center